-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Looking back at 2021, innovation can be said to be a key word in the entire pharmaceutical industry.
According to statistics, there are at least 61 new drugs approved by the China National Medical Products Administration in 2021, of which Chinese new drugs account for about 40%.
In 2021, Chinese local innovation The proportion of medicines reached a new high
.
In the context of the rapid development of the domestic innovative drug industry, the capital market continues to increase, and industry financing news continues.
In 2021, both financing events and amounts will show a substantial increase
.
On December 31, 2021, in rushing to the end of the year, Xuanzhu Bio, a wholly-owned subsidiary of Sihuan Pharmaceutical, announced that it has completed a round B investment of over 600 million yuan.
In the future, it will continue to increase the investment in the construction of innovative drug R&D pipelines to enhance independent sustainability Innovation ability
.
It is reported that this round of financing was led by Sunshine Life Insurance, Yifeng Capital, Zhongji Investment, Taijin Capital, SDIC Taikang, Haichuang Fund of Funds, Bank of China Capital, Jinjiang Xuanhong, Shaanxi Financial Holdings, Bay Letter Capital, Deno Capital , Huayi Capital and other investment institutions followed in the investment
.
According to data, Xuanzhu Biotechnology was established in 2002, and it is one of the few domestic platform-based innovative drug companies capable of independent research and development in the fields of small molecules and macromolecules at the same time
.
In 2008, Sihuan Pharmaceutical, a Hong Kong investment holding company engaged in the pharmaceutical business, formally announced the acquisition of 60% of Xuanzhu Biologics, and subsequently completed the wholly-owned acquisition of Xuanzhu Biologics in 2012, holding 100% of the shares
.
Xuanzhu Biology started its independent operation in 2018
.
In recent years, it has continued to grow and develop through acquisitions on the way to research and development of innovative drugs
.
For example, in December 2020, Xuanzhu Biotechnology acquired Beijing Kangming Biotech, a macromolecular biopharmaceutical company dedicated to the research and development of multifunctional antibody drugs such as innovative double antibodies and double antibodies ADC
.
At this point, Xuanzhu Biotech also has two major R&D platforms for small molecules and macromolecules, and has formed a complete new drug research and development system, covering small molecules, monoclonal antibodies, double antibodies, fusion proteins, double antibodies-ADC, protein degradation and other fields , Have the ability to continue R&D and output
.
From the perspective of product pipeline, Xuanzhu Bio focuses on cutting-edge new drug research and development fields such as tumor, metabolism, anti-infection, and digestion, and is committed to the development of 1.
1 innovative drugs.
.
As of now, Xuanzhu Bio has more than 25 products under development, 2 of which are in the NDA stage.
Among them, the new drug Anaprazole Sodium for the treatment of duodenal ulcer has completed the NDA application and accepted it.
It is expected to be approved in the second half of 2022.
Batch listing
.
In addition, the SGLT-2 inhibitor plus agliflozin for the treatment of diabetes will soon be submitted for NDA; the core product new generation CDK4/6 inhibitor Pirosinib and ALK/ROS1 dual target inhibitor XZP-3621 have all started phase III Clinical; In addition, 11 products have entered clinical phase I-III at the same time.
In the future, 1-2 projects will continue to enter the clinical development phase each year
.
In addition, Xuanzhu Biology has also actively deployed its international BD business in recent years.
The company has transferred the commercialization rights of the macromolecular biopharmaceutical Pertuzumab biosimilar (KM118) to the strategic investor Shuanglu Pharmaceutical.
It is expected to start clinical trials in the near future.
Phase III: The company is also continuing to carry out external authorizations for various therapeutic projects such as oncology, NASH, and anti-infection
.
Due to its rich R&D pipeline, the capital also highly recognizes the development potential of Xuanzhu Biology
.
In 2020, Xuanzhu Biotechnology has received strategic investment from SDIC Investment, and completed a round of financing of 963 million yuan, with a valuation of 4.
5 billion yuan
.
Now plus this round of financing, Xuanzhu Bio's valuation will reach 7 billion yuan
.
According to statistics, there are at least 61 new drugs approved by the China National Medical Products Administration in 2021, of which Chinese new drugs account for about 40%.
In 2021, Chinese local innovation The proportion of medicines reached a new high
.
In the context of the rapid development of the domestic innovative drug industry, the capital market continues to increase, and industry financing news continues.
In 2021, both financing events and amounts will show a substantial increase
.
On December 31, 2021, in rushing to the end of the year, Xuanzhu Bio, a wholly-owned subsidiary of Sihuan Pharmaceutical, announced that it has completed a round B investment of over 600 million yuan.
In the future, it will continue to increase the investment in the construction of innovative drug R&D pipelines to enhance independent sustainability Innovation ability
.
It is reported that this round of financing was led by Sunshine Life Insurance, Yifeng Capital, Zhongji Investment, Taijin Capital, SDIC Taikang, Haichuang Fund of Funds, Bank of China Capital, Jinjiang Xuanhong, Shaanxi Financial Holdings, Bay Letter Capital, Deno Capital , Huayi Capital and other investment institutions followed in the investment
.
According to data, Xuanzhu Biotechnology was established in 2002, and it is one of the few domestic platform-based innovative drug companies capable of independent research and development in the fields of small molecules and macromolecules at the same time
.
In 2008, Sihuan Pharmaceutical, a Hong Kong investment holding company engaged in the pharmaceutical business, formally announced the acquisition of 60% of Xuanzhu Biologics, and subsequently completed the wholly-owned acquisition of Xuanzhu Biologics in 2012, holding 100% of the shares
.
Xuanzhu Biology started its independent operation in 2018
.
In recent years, it has continued to grow and develop through acquisitions on the way to research and development of innovative drugs
.
For example, in December 2020, Xuanzhu Biotechnology acquired Beijing Kangming Biotech, a macromolecular biopharmaceutical company dedicated to the research and development of multifunctional antibody drugs such as innovative double antibodies and double antibodies ADC
.
At this point, Xuanzhu Biotech also has two major R&D platforms for small molecules and macromolecules, and has formed a complete new drug research and development system, covering small molecules, monoclonal antibodies, double antibodies, fusion proteins, double antibodies-ADC, protein degradation and other fields , Have the ability to continue R&D and output
.
From the perspective of product pipeline, Xuanzhu Bio focuses on cutting-edge new drug research and development fields such as tumor, metabolism, anti-infection, and digestion, and is committed to the development of 1.
1 innovative drugs.
.
As of now, Xuanzhu Bio has more than 25 products under development, 2 of which are in the NDA stage.
Among them, the new drug Anaprazole Sodium for the treatment of duodenal ulcer has completed the NDA application and accepted it.
It is expected to be approved in the second half of 2022.
Batch listing
.
In addition, the SGLT-2 inhibitor plus agliflozin for the treatment of diabetes will soon be submitted for NDA; the core product new generation CDK4/6 inhibitor Pirosinib and ALK/ROS1 dual target inhibitor XZP-3621 have all started phase III Clinical; In addition, 11 products have entered clinical phase I-III at the same time.
In the future, 1-2 projects will continue to enter the clinical development phase each year
.
In addition, Xuanzhu Biology has also actively deployed its international BD business in recent years.
The company has transferred the commercialization rights of the macromolecular biopharmaceutical Pertuzumab biosimilar (KM118) to the strategic investor Shuanglu Pharmaceutical.
It is expected to start clinical trials in the near future.
Phase III: The company is also continuing to carry out external authorizations for various therapeutic projects such as oncology, NASH, and anti-infection
.
Due to its rich R&D pipeline, the capital also highly recognizes the development potential of Xuanzhu Biology
.
In 2020, Xuanzhu Biotechnology has received strategic investment from SDIC Investment, and completed a round of financing of 963 million yuan, with a valuation of 4.
5 billion yuan
.
Now plus this round of financing, Xuanzhu Bio's valuation will reach 7 billion yuan
.
